|
| 35664753 | A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. | Front Oncol | 2022 |
| 32793389 | A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. | Cell Discov | 2020 |
| 31974273 | Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. | Mol Cancer Ther | 2020 |
| 31018997 | SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer. | Mol Cancer Ther | 2019 |
| 28817691 | Rac2 is required for alternative macrophage activation and bleomycin induced pulmonary fibrosis; a macrophage autonomous phenotype. | PLoS One | 2017 |
| 28137841 | Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. | Proc Natl Acad Sci U S A | 2017 |
| 26938241 | PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. | PLoS One | 2016 |
| 28881723 | Association of high microvessel α<sub>v</sub>β<sub>3</sub> and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. | Oncotarget | 2016 |
| 27496136 | Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. | Mol Cancer Ther | 2016 |
| 25578041 | Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. | Cancer Chemother Pharmacol | 2015 |
| 24162827 | PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. | J Neurooncol | 2014 |
| 25425962 | Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12)â¿¿V-Ha-Ras transgenic mouse glioma model. | Cancer Cell Int | 2014 |
| 24982421 | MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. | J Biol Chem | 2014 |
| 25103499 | A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. | Mol Cancer Res | 2014 |
| 24770346 | Rac2 controls tumor growth, metastasis and M1-M2 macrophage differentiation in vivo. | PLoS One | 2014 |
| 24886428 | A PKC-SHP1 signaling axis desensitizes Fcγ receptor signaling by reducing the tyrosine phosphorylation of CBL and regulates FcγR mediated phagocytosis. | BMC Immunol | 2014 |
| 24881819 | PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. | Exp Cell Res | 2014 |
| 22906884 | Purification and characterization of phosphoenolpyruvate carboxykinase from Raillietina echinobothrida, a cestode parasite of the domestic fowl. | Parasitology | 2013 |
| 23045271 | Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma. | Oncogene | 2013 |
| 19756573 | Guanidine hydrochloride and urea-induced unfolding of Brugia malayi hexokinase. | Eur Biophys J | 2010 |
| 18456347 | Molecular cloning and characterization of Plasmodium falciparum transketolase. | Mol Biochem Parasitol | 2008 |
| 18499511 | Molecular cloning and characterization of Brugia malayi hexokinase. | Parasitol Int | 2008 |
| 18001110 | DNA binding and topoisomerase II inhibitory activity of water-soluble ruthenium(II) and rhodium(III) complexes. | Inorg Chem | 2007 |